Nonradiographic Axial Spondyloarthritis
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis (COAST-X)
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as ixekizumab in biologic disease modifying antirheumatic drug (bDMARD) naïve participants with nonradiographic axial spondyloarthritis (nonrad-axSpA).
The results of this study are not yet available.
Your participation could last up to 1 ½ years and include 15 visits to the study center. After this study, you may be eligible to enter another study that could last up to 2 more years.
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participant must have diagnosis of nonradiographic axial spondyloarthritis (nr-axSpA)
Participant must be able to walk
Participant must have a history of back pain for ≥3 months that started before 45 years of age
Participants must have had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAIDS) for duration of 4 weeks or cannot tolerate NSAIDS.
Participants that are taking NSAIDS must be on a stable dose for at least 2 weeks prior to randomization
Participants must have a history of prior therapy for axSpA for at least 12 weeks prior to screening for the study
Participants must not have radiographic sacroiliitis
Participants must not have received any prior, or are currently receiving treatment with biologics, tumor necrosis factor inhibitors or other immunomodulatory agents
Female participants must not be pregnant or breastfeeding